Surmodics (SRDX)
(Delayed Data from NSDQ)
$26.17 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $26.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
SRDX 26.17 0.00(0.00%)
Will SRDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRDX
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
SRDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates
New Strong Buy Stocks for April 9th
Here's Why You Should Hold Surmodics (SRDX) Stock for Now
Other News for SRDX
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
Surmodics to Participate in Upcoming Investor Conferences in March and April
Surmodics Shareholders Approve Directors and Fiscal Oversight